Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
Reported Earlier, BeiGene Secures Global Licensing Agreement For Novel MAT2A Inhibitor SYH2039 To Target MTAP-Deleted Solid Tumors
SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.
SYH2039針對具有MTAP缺失突變的實體腫瘤，預計該突變存在於大約15%的所有癌症類型中，最常見的包括膠質母細胞瘤、胰腺癌和非小細胞肺癌。
"With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we're eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067. Together, these assets hold promise for advancing treatment across a range of solid tumors," said Lai Wang, Ph.D., Global Head of R&D at BeiGene.
"我們在行業中擁有最具活力的實體腫瘤產品組合之一，我們不斷評估與我們的戰略重點對齊並解決患者重大未滿足需求的機會。這種MAT2A抑制劑是我們實體腫瘤管線的寶貴補充，我們渴望探索其潛力，特別是與我們內部開發的PRMT5抑制劑BGb-58067聯合使用。綜合來看，這些資產有望推動治療跨越多個實體腫瘤區間,"百濟神州研發全球負責人Lai Wang博士表示。
譯文內容由第三人軟體翻譯。
